Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - darunavir - filmovertrukne tabletter - 75 mg

Union européenne - danois - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (som monohydrat) - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif er indiceret til behandling af voksne patienter med nyligt diagnosticeret kronisk fase (cp) philadelphia-kromosom-positiv kronisk myelogenous leukæmi (ph+ cml). cp, accelereret fase (ap), og blast fase (bp) ph+ cml, der tidligere er behandlet med en eller flere tyrosin kinase inhibitor(s) [tki(s)], og for hvem imatinib, nilotinib og dasatinib er ikke anset som egnede behandlingsmuligheder.

Union européenne - danois - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se afsnit 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Union européenne - danois - EMA (European Medicines Agency)

hra pharma rare diseases - ketoconazol - cushing syndrome - antimykotika til systemisk brug - ketoconazol hra er indiceret til behandling af endogent cushings syndrom hos voksne og unge over 12 år.

Union européenne - danois - EMA (European Medicines Agency)

mylan pharmaceuticals limited - lopinavir, ritonavir - hiv infektioner - antivirale midler til systemisk anvendelse - lopinavir/ritonavir angives i kombination med andre antiretrovirale lægemidler til behandling af human immundefekt virus (hiv-1) inficeret voksne, unge og børn over 2 år. valget af lopinavir/ritonavir til at behandle proteasehæmmer oplevet hiv-1-inficerede patienter bør være baseret på individuelle viral resistens test og historie behandling af patienter.

Union européenne - danois - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Union européenne - danois - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - hiv infektioner - antivirale midler til systemisk anvendelse - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Union européenne - danois - EMA (European Medicines Agency)

viiv healthcare bv - fosamprenavir calcium - hiv infektioner - antivirale midler til systemisk anvendelse - telzir i kombination med lavdosis ritonavir er indiceret til behandling af human-immunodeficiency-virus-type-1-infected voksne, unge og børn på seks år og derover i kombination med andre antiretrovirale lægemidler. i moderat antiretroviral-erfarne voksne, telzir i kombination med en lav dosis ritonavir har ikke vist sig at være så effektiv som lopinavir / ritonavir. ingen sammenlignende undersøgelser har været gennemført i børn og unge. i stærkt forbehandles patienter, brug af telzir i kombination med en lav dosis ritonavir er ikke blevet tilstrækkeligt undersøgt. i protease-inhibitor-erfarne patienter, valg af telzir bør være baseret på individuelle viral resistens test og behandling, historie.

Union européenne - danois - EMA (European Medicines Agency)

astrazeneca ab - natrium zirconium cyclosilicate - hyperkaliæmi - alle andre terapeutiske produkter - lokelma er indiceret til behandling af hyperkalaemia i voksne patienter.

Union européenne - danois - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.